

Precision Oncology and Personalized Cancer Treatment: Advances, Challenges and Future Prospects

Ingrid A. Solberg

Centre for Applied Physics, Nordhaven University, Oslo, Norway

Received: 15/02/2026 ; Accepted: 09/06/2026 ; Published: 28/08/2026

Abstract

Precision oncology represents a major transformation in modern cancer medicine, shifting treatment from generalized disease categories toward individualized therapeutic strategies based on the molecular, genetic, clinical, and biological characteristics of each patient's tumor. Conventional cancer treatment has traditionally relied on tumor location, histological classification, and standardized treatment protocols. Although these approaches have improved survival for many patients, substantial differences in treatment response, disease progression, drug resistance, and toxicity demonstrate that patients with apparently similar cancers may have fundamentally different biological diseases. Precision oncology addresses this heterogeneity by integrating genomic sequencing, transcriptomics, proteomics, epigenomics, liquid biopsy, tumor profiling, imaging, artificial intelligence, and clinical information to identify biomarkers and therapeutic targets. This research paper examines the conceptual foundations of precision oncology and evaluates advances in molecular diagnosis, targeted therapy, immunotherapy, companion diagnostics, circulating tumor DNA, pharmacogenomics, and artificial intelligence. Particular attention is given to the use of next-generation sequencing for identifying actionable genomic alterations and matching patients with targeted treatments. The paper also discusses tumor heterogeneity, acquired resistance, minimal residual disease, liquid biopsies, and longitudinal molecular monitoring as critical components of personalized cancer management. Precision oncology has generated important advances in several cancers, including breast, lung, colorectal, melanoma, hematological malignancies, and selected rare cancers. Nevertheless, significant challenges remain, including unequal access to genomic testing, interpretation of variants of uncertain significance, limited availability of targeted therapies, cost, data privacy, tumor evolution, and disparities in clinical infrastructure. Future precision oncology is likely to integrate multi-omics, spatial biology, artificial intelligence, digital pathology, real-world evidence, and adaptive clinical trials. The paper concludes that precision oncology should not be viewed merely as genetic testing followed by targeted therapy. Rather, it represents a dynamic model of cancer care in which tumor biology is repeatedly characterized and treatment is adapted as disease evolves.

Keywords: Precision Oncology, Personalized Cancer Treatment, Cancer Genomics, Targeted Therapy, Immunotherapy, Biomarkers, Next-Generation Sequencing, Liquid Biopsy, Artificial Intelligence, Pharmacogenomics, Precision Medicine

1. Introduction

Cancer is not a single disease but a diverse group of disorders characterized by uncontrolled cellular proliferation, genomic instability, altered cellular signaling, immune evasion, and progressive changes in the tumor microenvironment.

Traditional cancer classification has largely relied on:

- Anatomical location
- Histological type
- Tumor stage
- Grade
- Clinical characteristics

These classifications remain fundamental to cancer care. However, advances in molecular biology have demonstrated that tumors originating in the same organ can possess substantially different genetic and biological characteristics.

For example, two patients with the same anatomical type of cancer may have different:

$$\begin{aligned}
 &[\\
 &\text{\text{Mutations}} \\
 &+ \\
 &\text{\text{Gene}} \qquad \qquad \qquad \text{Expression} \\
 &+ \\
 &\text{\text{Immune}} \qquad \qquad \qquad \text{Profiles} \\
 &+ \\
 &\text{\text{Tumor}} \qquad \qquad \qquad \text{Microenvironments} \\
 &]
 \end{aligned}$$

Consequently, they may respond differently to the same treatment.

Precision oncology emerged in response to this biological heterogeneity.

Its fundamental objective is:

$$\begin{aligned}
 &[\\
 &\boxed{ \\
 &\text{\text{Right}} \qquad \qquad \qquad \text{Treatment} \\
 &+ \\
 &\text{\text{Right}} \qquad \qquad \qquad \text{Patient} \\
 &+ \\
 &\text{\text{Right}} \qquad \qquad \qquad \text{Time} \\
 &] \\
 &]
 \end{aligned}$$

rather than applying identical treatment strategies to all patients with the same broad cancer diagnosis.

Precision oncology uses molecular and clinical information to identify the characteristics that distinguish one tumor from another.

A simplified precision-oncology pathway is:

$$\begin{aligned}
 &[\\
 &\text{\text{Patient}}
 \end{aligned}$$

$\rightarrow$	
Tumor	Profiling}
$\rightarrow$	
Biomarker	Identification}
$\rightarrow$	
Therapeutic	Matching}
$\rightarrow$	
Treatment	
$\rightarrow$	
Molecular	Monitoring}
$\rightarrow$	
Treatment	Adaptation}.
]	

This model increasingly incorporates genomic sequencing, liquid biopsy, artificial intelligence, imaging, pathology, immunology, and real-world clinical data.

The field has produced important successes, but precision oncology is not without limitations. Identifying a molecular alteration does not necessarily mean that an effective treatment exists. Tumors evolve, therapeutic resistance develops, and access to advanced molecular diagnostics remains uneven.

This paper therefore examines precision oncology as a comprehensive approach to personalized cancer treatment, including its scientific foundations, clinical applications, technological advances, challenges, and future prospects.

2. From Conventional Oncology to Precision Oncology

Conventional oncology generally uses population-level evidence.

If a clinical trial demonstrates that a particular treatment improves outcomes for patients with a specific cancer, the treatment may become part of standard practice.

However, population-level effectiveness does not guarantee an identical response in every patient.


Precision oncology adds another layer:

$$\begin{array}{c}
 [\\
 \text{Population Evidence} \\
 + \\
 \text{Individual Tumor Biology} \\
 \rightarrow \\
 \text{Personalized Treatment} \\
]
 \end{array}$$

The transformation can be described through three major stages.

Traditional Medicine

$$\begin{array}{c}
 [\\
 \text{Cancer Type} \\
 \rightarrow
 \end{array}$$



3. Cancer Genomics

Cancer genomics is one of the foundations of precision oncology.

Cancer cells accumulate genetic alterations that can influence:

- Cell proliferation
- DNA repair
- Apoptosis
- Metabolism
- Immune interactions
- Metastasis
- Drug sensitivity

Some alterations function as **driver mutations**, meaning they contribute directly to tumor development or progression.

Others may be **passenger mutations** that do not provide a major growth advantage.

The identification of clinically meaningful driver alterations is therefore central to precision treatment.

4. Next-Generation Sequencing

Next-generation sequencing (NGS) has transformed the ability to analyze tumor genomes.

NGS can investigate:

- Single-nucleotide variants
- Insertions and deletions
- Copy-number alterations
- Gene fusions
- Selected structural variants
- Mutational signatures

Testing strategies may include:

Targeted Panels

Analyze a selected group of clinically relevant genes.

Whole-Exome Sequencing

Analyzes protein-coding regions of the genome.

Whole-Genome Sequencing

Provides broader genomic information.

The choice depends on clinical objectives, available resources, tissue quantity, and testing strategy.

5. Biomarkers in Precision Oncology

A biomarker is a measurable biological characteristic that can provide information about disease or treatment response.

Cancer biomarkers may include:

- Genetic mutations
- Protein expression
- Gene amplification
- Gene fusions
- Tumor mutational burden
- Microsatellite instability
- Immune markers
- Circulating tumor DNA

Biomarkers can serve different purposes.

Diagnostic Biomarkers

Help identify or characterize disease.

Prognostic Biomarkers

Provide information about expected disease outcome.

Predictive Biomarkers

Help identify patients who are more likely to benefit from a particular treatment.

The distinction is clinically important.


6. Targeted Cancer Therapy

Targeted therapies are designed to interfere with specific molecular pathways involved in tumor growth.

Examples include therapies targeting:

- Receptor tyrosine kinases
- Growth-factor signaling
- Hormone receptors
- DNA-repair pathways
- Angiogenesis
- Specific oncogenic fusion proteins

The general model is:



This differs from conventional cytotoxic chemotherapy, which often affects rapidly dividing cells more broadly.

Targeted therapy therefore represents one of the clearest applications of precision oncology.

7. Precision Oncology in Breast Cancer


Breast cancer demonstrates how molecular classification has changed treatment.

Breast tumors may differ in:

- Estrogen receptor status
- Progesterone receptor status
- HER2 status
- Genomic characteristics
- Proliferation patterns

Treatment decisions can therefore incorporate tumor biology in addition to anatomical staging.

For example:



Similarly, hormone-receptor status influences endocrine treatment strategies.

This illustrates how molecular classification can influence treatment selection.

8. Precision Oncology in Lung Cancer

Non-small-cell lung cancer has become an important model for molecularly guided treatment.

Clinically relevant alterations may occur in genes such as:

- EGFR
- ALK
- ROS1
- BRAF
- MET
- RET
- KRAS
- NTRK

Depending on the specific molecular profile, targeted therapies may be available.

Consequently, comprehensive molecular testing can be particularly important for selected patients with advanced disease.

9. Precision Oncology in Colorectal Cancer


Colorectal cancer also demonstrates the importance of molecular profiling.

Important biomarkers may include:

- KRAS
- NRAS
- BRAF
- Mismatch repair status
- Microsatellite instability

These characteristics can influence treatment selection.

For example:



10. Precision Oncology in Melanoma

Melanoma has been a major success story for both targeted therapy and immunotherapy.

Certain melanomas contain activating alterations in the BRAF pathway.

Molecular testing can therefore help identify patients who may benefit from pathway-directed treatment.

At the same time, immune checkpoint inhibitors have transformed treatment for many patients. This demonstrates that precision oncology does not necessarily mean only gene-targeted therapy.

It also includes **immune-based patient selection**.

11. Immunotherapy and Precision Oncology

Cancer immunotherapy attempts to activate or strengthen the immune system's ability to recognize and attack tumor cells.

Important therapeutic approaches include:

- Immune checkpoint inhibitors
- Adoptive cell therapy
- CAR-T-cell therapy
- Cancer vaccines
- Bispecific antibodies

Precision oncology contributes by identifying patients more likely to respond.

Relevant biomarkers can include:


- PD-L1 expression
- Microsatellite instability
- Tumor mutational burden
- Specific immune signatures

However, biomarker interpretation is complex, and no single marker perfectly predicts response in all cancers.

12. CAR-T Cell Therapy

CAR-T therapy represents an individualized form of cellular cancer treatment.

A simplified process is:



The patient's immune cells are engineered to recognize specific tumor-associated targets.

CAR-T therapy has demonstrated particularly important clinical benefits in selected hematological malignancies.

However, challenges include:

- Manufacturing complexity
- Treatment cost
- Cytokine release syndrome
- Neurological toxicities
- Antigen escape
- Limited effectiveness against many solid tumors

- Treatment selection
- Detecting resistance
- Monitoring disease
- Identifying minimal residual disease
- Tracking tumor evolution

The potential model is:

$$\begin{array}{c}
 [\\
 \text{\texttt{\text{Treatment}}} \\
 \rightarrow \\
 \text{\texttt{MRD Testing}} \\
 \rightarrow \\
 \begin{cases} \\
 \text{\texttt{No detectable disease}} \\
 \text{\texttt{Molecular residual disease}} \\
 \end{cases} \\
]
 \end{array}$$

MRD assessment is especially important in certain hematological malignancies and is increasingly being studied across solid tumors.

16. Tumor Heterogeneity

One of the greatest challenges in precision oncology is that a tumor is not necessarily biologically uniform.

Different regions may contain different subclones.

A tumor can therefore be represented as:

$$\begin{array}{c}
 [\\
 T = \{C_1, C_2, C_3, \dots, C_n\} \\
]
 \end{array}$$

where each (C_i) represents a distinct cellular population.

Treatment may eliminate sensitive cells while resistant clones survive.

This can result in:

$$\begin{array}{c}
 [\\
 \text{\texttt{Treatment}} \\
 \rightarrow \\
 \text{\texttt{Sensitive Clone Elimination}} \\
 \rightarrow \\
 \text{\texttt{Resistant Clone Expansion}}. \\
]
 \end{array}$$

Tumor heterogeneity is therefore a major driver of treatment failure.

17. Acquired Resistance

Cancer cells can develop resistance through multiple mechanisms.

These include:

- Secondary mutations
- Alternative signaling pathways
- Gene amplification
- Phenotypic changes
- Immune escape

- Drug efflux
- Changes in the tumor microenvironment

Precision oncology increasingly requires longitudinal monitoring rather than one-time molecular profiling.

The treatment model may therefore become:

[
 $\text{\text{Profile}}$
 $\rightarrow$
 $\text{\text{Treat}}$
 $\rightarrow$
 $\text{\text{Monitor}}$
 $\rightarrow$
 $\text{\text{Re-profile}}$
 $\rightarrow$
 $\text{\text{Adapt}}$.
]

18. Pharmacogenomics

Pharmacogenomics examines how genetic variation influences response to medicines.

In oncology, patient genetics may influence:

- Drug metabolism
- Drug toxicity
- Treatment response

This can help reduce the risk of severe adverse reactions in selected contexts.

Pharmacogenomics therefore complements tumor genomics.

[
 $\text{\text{Tumor Genome}}$
 $+$
 $\text{\text{Patient Genome}}$
 $\rightarrow$
 $\text{\text{Personalized Treatment Strategy}}$.
]

19. Multi-Omics Precision Oncology

Genomics provides only one layer of biological information.

Advanced precision oncology increasingly considers:

- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Epigenomics
- Microbiomics

These can be integrated as:

$$\begin{bmatrix} \text{Multi-Omics} \\ G+T+P+M+E+\cdots \end{bmatrix}$$

where each layer provides complementary biological information.

The objective is to develop a more complete representation of tumor biology.

20. Artificial Intelligence in Precision Oncology

Artificial intelligence can help analyze the enormous datasets generated by precision medicine.

AI may be used for:

- Genomic interpretation
- Imaging analysis
- Pathology
- Biomarker discovery
- Treatment prediction
- Drug development
- Clinical decision support

For example:

$$\begin{bmatrix} \text{Genomics} \\ + \\ \text{Pathology} \\ + \\ \text{Imaging} \\ + \\ \text{Clinical Data} \\ \rightarrow \\ \text{AI-Based Prediction} \end{bmatrix}$$

Machine learning may identify complex patterns that are difficult to recognize using traditional statistical methods.

21. Digital Pathology

Pathology remains essential to cancer diagnosis.

Whole-slide imaging allows tissue samples to be digitized and analyzed computationally.

AI can assist with:

- Tumor identification
- Cell classification
- Biomarker quantification
- Histological grading
- Spatial analysis

Digital pathology can therefore complement molecular profiling.

The future diagnostic workflow may combine:

$$\begin{array}{c} [\\ \text{\text{Pathology}} \\ + \\ \text{\text{Genomics}} \\ + \\ \text{\text{Imaging}} \\ + \\ \text{\text{AI}}. \\] \end{array}$$

22. Spatial Biology

Tumors exist within complex microenvironments.

Spatial biology technologies investigate where cells, genes, and proteins are located within tissue.

This is important because two tumors may contain similar cell types but arrange them differently.

Spatial analysis can investigate:

- Tumor cells
- Immune cells
- Stromal cells
- Blood vessels
- Signaling pathways

This may reveal why some tumors respond to treatment while others do not.

23. Precision Oncology and the Tumor Microenvironment

The tumor microenvironment includes:

- Immune cells
- Fibroblasts
- Blood vessels
- Extracellular matrix
- Signaling molecules

It can influence:

- Tumor growth
- Metastasis
- Immune response
- Drug penetration
- Treatment resistance

Consequently:

$$\begin{array}{c} [\\ \text{\text{Tumor Biology}} \end{array}$$

\neq
\text{Tumor Cells Alone}.

]

Precision oncology must increasingly consider the complete tumor ecosystem.

24. Precision Oncology and Rare Cancers

Rare cancers create particular treatment challenges because traditional large clinical trials may be difficult to conduct.

Molecular profiling can sometimes identify actionable alterations that occur across different anatomical cancer types.

This has contributed to the concept of **tumor-agnostic therapy**, in which treatment eligibility may depend more on a specific molecular alteration than on the tissue of origin.

This represents a major conceptual shift:

Conclusion

Precision oncology represents a fundamental change in the philosophy and practice of cancer treatment. Rather than treating patients solely according to tumor location, histological classification, and stage, modern oncology increasingly incorporates the molecular and biological characteristics of individual tumors.

Advances in next-generation sequencing, targeted therapies, immunotherapy, liquid biopsy, circulating tumor DNA, digital pathology, radiomics, multi-omics, spatial biology, and artificial intelligence have created new opportunities for personalized cancer care.

Precision oncology has already demonstrated meaningful clinical value in selected cancers where actionable molecular alterations can be matched to effective therapies. Yet its promise should not be overstated. Tumor heterogeneity, resistance, incomplete biomarker knowledge, high costs, unequal access, and the complexity of interpreting molecular data remain substantial obstacles.

References

1. André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., et al. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *New England Journal of Medicine*, 380, 1929–1940.
2. Ashley, E. A. (2016). Towards precision medicine. *Nature Reviews Genetics*, 17, 507–522.
3. Baselga, J. (2006). Targeting the molecular diversity of cancer: A new era in drug development. *Clinical Cancer Research*, 12, 526–531.
4. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372, 793–795.
5. Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., & Adamo, B. (2017). Genomic medicine frontier in breast cancer. *Journal of Clinical Oncology*, 35, 315–317.
6. Esposito, A., Criscitiello, C., & Curigliano, G. (2019). Highlights from the latest advances in precision oncology. *Current Opinion in Oncology*, 31, 477–484.

7. Garraway, L. A., & Verweij, J. (2015). Precision oncology: An emerging paradigm for the treatment of cancer. *Clinical Cancer Research*, 21, 190–196.
8. Hyman, D. M., Taylor, B. S., & Baselga, J. (2017). Implementing genome-driven oncology. *Cell*, 168, 584–599.
9. Kamps, R., Brandão, R. D., Bosch, B. J., Paulussen, A. D. C., Xanthoulea, S., Blok, M. J., et al. (2017). Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. *International Journal of Molecular Sciences*, 18, 308.
10. Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020). Molecular profiling for precision cancer therapies. *Genome Medicine*, 12, 8.
11. Meric-Bernstam, F., Brusco, L., Shaw, K., Horowitz, C., & Aktas, I. (2015). Feasibility of large-scale genomic testing to facilitate precision oncology. *JAMA Oncology*, 1, 990–997.
12. McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: Past, present, and the future. *Cell*, 168, 613–628.
13. Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., et al. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*, 24(Suppl. 2), S26–S35.
14. Rotow, J., & Bivona, T. G. (2017). Understanding and targeting resistance mechanisms in NSCLC. *Nature Reviews Cancer*, 17, 637–658.
15. Schwaederlé, M., & Kurzrock, R. (2015). Using biomarkers to guide clinical decisions: The promise and challenges of precision medicine. *Nature Reviews Clinical Oncology*, 12, 703–712.
16. Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. *Nature Reviews Clinical Oncology*, 14, 531–548.
17. Tannock, I. F., & Hickman, J. A. (2016). Limits to personalized cancer medicine. *New England Journal of Medicine*, 375, 1289–1294.
18. Vokes, N. I., & Camidge, D. R. (2020). The evolving landscape of molecular testing in lung cancer. *Journal of Clinical Oncology*, 38, 1055–1066.
19. West, H. J., & McCormick, M. (2021). Precision medicine in oncology: Current approaches and future directions. *CA: A Cancer Journal for Clinicians*.
20. Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. *New England Journal of Medicine*, 377, 2500–2501.